{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Tanomastat",
  "nciThesaurus": {
    "casRegistry": "179545-77-8",
    "chebiId": "",
    "chemicalFormula": "C23H19ClO3S",
    "definition": "A biphenyl matrix metalloproteinase (MMP) inhibitor (MMPI) with potential antineoplastic activity. Tanomastat inhibits MMP-2, MMP-3, and MMP-9, inhibiting extracellular matrix degradation and potentially inhibiting angiogenesis, tumor growth and invasion, and metastasis. MMPs consist of at least 18 zinc-containing endo-proteinases that are capable of degrading collagen and proteoglycan.",
    "fdaUniiCode": "AM1ZX94EXH",
    "identifier": "C1705",
    "preferredName": "Tanomastat",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C1970"
    ],
    "synonyms": [
      "(S)-3-[(4'-Chloro-4-biphenylyl)carbonyl]-2-[(phenylthio)methyl]propionic acid",
      "4-[4-(chlorophenyl)phenyl]-4-oxo-2S-(phenylthiomethyl) butanoic acid",
      "BAY 12-9566",
      "BAY-12-9566",
      "TANOMASTAT",
      "Tanomastat"
    ]
  }
}